Oral abstracts

ESVCP – European Society of Veterinary Clinical Pathology
Wednesday 1 September  
14.40 ESVCP-O-1 Cerná Platelet indices and their dynamics in dogs with systemic inflammatory response syndrome - prospective study
14.55 ESVCP-O-3 Bech Reticulated platelets and Nucleic Acid Containing Units (NACU) in dogs with cancer
15.10 ESVCP-O-4 Rompf Biological variation of plasma procalcitonin in clinically healthy dogs
15.25 ESVCP-O-5 Ruíz-Tapia Urinary C reactive protein in dogs with chronic kidney disease: preliminary study
15.40 ESVCP-O-6 Zoia A simple prognostic score identifying mortality in canine immune-mediated haemolytic anaemia (IMHA)
16.30 ESVCP-O-7 Broadbridge Can we use urine pH or the haem dipstick result to predict bacteriuria in cats and dogs with inactive urine sediments?
ESVCN – European Society of Veterinary Comparative  Nutrition
Wednesday 1 September  
12.05 ESVCN-O-1 Steffen High intake of sodium chloride for 28 days causes no effect on serum FGF-23 concentrations in cats
12.20 ESVCN-O-3 German Beyond the scale: a retrospective observational study of cats and dogs presenting to a referral centre with severe obesity
ESVIM – European Society of Veterinary Internal Medicine
Wednesday 1 September  
08.00 ESVIM-O-1 Lebastard Association between bronchoalveolar lavage fluid quantitative bacterial culture results and antibiotic requirement in dogs with lower respiratory tract signs
08.15 ESVIM-O-2 Gareis Evaluation of pulmonary function by whole-body plethysmography for therapy monitoring in cats with chronic bronchial disease
08.30 ESVIM-O-3 Fastrès Serum and bronchoalveolar lavage fluid concentration of osteopontin and fibronectin in West Highland white terriers either affected with canine idiopathic pulmonary fibrosis or healthy and other terriers non predisposed to the disease
09.00 ESVIM-O-4 Carluen Incidence and characterization of penetration and aspiration in dogs using videofluoroscopic swallow studies
09.15 ESVIM-O-5 Rodrigues Antimicrobial discontinuation in dogs with acute aspiration pneumonia based on normal C-Reactive Protein and clinical improvement
09.30 ESVIM-O-6 Machiels Study of the use of IDEXX PROCYTE for total and differential cellular counts  of bronchoalveolar lavage fluid in healthy dogs
09.45 ESVIM-O-7 Kouki Bile acids in saliva of dogs with respiratory diseases and of healthy dogs pre- and post-feeding
10.00 ESVIM-O-8 Biénès Effect of bronchoalveolar lavage on lung ultrasound and radiography in healthy dogs
10.15 ESVIM-O-9 Lyssens Gentamicin concentrations in bronchoalveolar lavage and serum in healthy dogs after inhalation therapy
10.30 ESVIM-O-10 Biénès Gentamicin concentration in nasal lavage in healthy dogs after inhalation therapy
11.20 ESVIM-O-11 Vangrinsven Comparison of culture- dependent and -independent methods on nasal swabs in dogs with nasal discharge
11.35 ESVIM-O-12 Vangrinsven Alterations of the nasal microbiota in dogs with sinonasal aspergillosis before and after cure and comparison with chronic idiopathic rhinitis
11.50 ESVIM-O-13 Idalan Comparison of immunohematological diagnostic tests including six different Coombs’ test methods in dogs suspected to have immune-mediated hemolytic anemia
12.05 ESVIM-O-14 Bouzouraa Diagnostic utility of C-reactive protein on plasma and abdominal fluid in dogs with ascites
12.20 ESVIM-O-15 Work Shar Pei auto-inflammatory disorder (SPAID) in the United Kingdom - a retrospective survey
12.35 ESVIM-O-16 Broughton Diagnoses and outcomes associated with ionised hypercalcaemia in a referral population of cats
Thursday 2 September  
08.00 ESVIM-O-17 Tumbarello A prospective randomized trial of methylprednisolone with or without cyclosporine or mycophenolate mofetil for the treatment of immune-mediated haemolytic anaemia in 43 dogs
08.15 ESVIM-O-18 Moretto Suspected hypertensive encephalopathy in cats with systemic hypertension
08.30 ESVIM-O-19 Lamminen Pregabalin alleviates feline anxiety and fear during transport and veterinary visits – a clinical field study
08.45 ESVIM-O-20 Bunn Prevalence and causes of fasting hypertriglyceridaemia in Australian Miniature Schnauzers
ISCAID - International Society for Companion Animal Infectious Diseases
Thursday 2 September  
14.15 ISCAID-O-1 Schwedinger Results of a study about vaccination decision of dog owners
14.30 ISCAID-O-2 Jähne Detection of mutated and non-mutated feline coronaviruses in cats without feline infectious peritonitis
14.45 ISCAID-O-3 Krafft Report of one year surveillance of SARS-CoV-2 detection by PCR in dogs and cats with various exposure risk
15.00 ISCAID-O-4 Walter-Weingärtner Comparison of eight commercially available point-of-care tests to detect canine parvovirus in faeces of dogs
15.15 ISCAID-O-5 Spiri Modified-live FCV vaccination reduces viral RNA loads, duration of RNAemia and the severity of clinical signs after heterologous FCV Challenge
15.30 ISCAID-O-6 Vahlenkamp High prevalence of antibodies against feline morbillivirus type 1 and 2 and association with FLUTD and increased blood creatinine concentrations in domestic cats
15.45 ISCAID-O-7 Griebsch Emerging canine leptospirosis in NSW, Australia
16.00 ISCAID-O-8 Rigo Experimental infection by leptospira australis in cats
16.30 ISCAID-O-9 Taylor Exploration of the role of Leptospira spp. in cats with chronic kidney disease (CKD)
16.45 ISCAID-O-10 Bouzouraa Epidemiological, clinical and biological impact of hemoplasmas in cancer-bearing dogs: A case-control study on 324 cases
17.00 ISCAID-O-11 Schmitt Dissemination of blaOXA-48 carbapenemase- and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a Swiss companion animal clinic
17.15 ISCAID-O-12 Steffensen Methylprednisolone induces neutrophil extracellular trap formation and enhances bactericidal effect of canine neutrophils
17.30 ISCAID-O-13 McCartin Evaluation of serum 25-hydroxyvitamin D and C-reactive protein as biomarkers in dogs with coccidioidomycosis
17.45 ISCAID-O-14 Willi Expanded geographic occurrence of Cytauxzoon sp. infection in domestic cats in Switzerland and detection of the infection in felid samples collected two decades ago
18.00 ISCAID-O-15 Gentil Prevalence of Taeniidae eggs and Echinococcus multilocularis in faecal samples of dogs in Europe
SCH – Society of Comparative Hepatology 
Thursday 2 September  
11.05 SCH-O-1 Dröes Prevalence of portal vein thrombosis in 153 dogs with chronic hepatitis: 2009-2019
11.20 SCH-O-2 Yamkate Immunohistochemical expression of caspase-3 and malondialdehyde in archived liver specimens from dogs with chronic hepatitis
11.35 SCH-O-3 Brunero Investigation of risk factors for gallbladder mucocoele development in Border Terriers; a UK-based, online owner survey
11.50 SCH-O-4 Jaffey Clinical findings and prognostic variables in dogs from Asia with gallbladder mucocele
12.05 SCH-O-5 Phillips Dogs with congenital portosystemic shunts have altered amino acid profiles compared to healthy dogs
12.20 SCH-O-6 Devriendt Plasma amino acid profiles in dogs with closed extrahepatic portosystemic shunts improve but remain abnormal three months after successful gradual attenuation
12.35 SCH-O-7 Devriendt Serum vitamin concentrations suggest incomplete restoration of liver function three months after successful gradual attenuation of extrahepatic shunts in dogs
ESVC – European Society of Veterinary Cardiology
Thursday 2 September  
09.15 ESVC-O-1 Bagardi Circulating miRNAs as potential biomarkers of early myxomatous mitral valve disease in Cavalier King Charles Spaniels
09.30 ESVC-O-2 Wesselowski Use of physical examination, electrocardiography, radiography and biomarkers to predict stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels
09.45 ESVC-O-3 Grosso Prognostic significance of different echocardiographic parameters of left atrial size in dogs with asymptomatic myxomatous mitral valve disease
10.00 ESVC-O-4 Partington The effect of obesity and subsequent weight loss on cardiac structure and function in dogs
10.15 ESVC-O-5 Safian Performance of different echocardiographic measurements of left atrial size by observers with different levels of experience
11.20 ESVC-O-6 Hezzell Teaching vets to be EPIC: validation of a focussed echocardiographic training program for general practitioners - the FEET-FIRST Study
11.35 ESVC-O-7 Giraud Evaluation of point-of-care ultrasound performed by non-cardiologists for diagnosis of degenerative mitral valve disease in dogs presented to the cardiology service
11.50 ESVC-O-8 Saponaro A new auscultatory finding confirmed by phonocardiography in cats with obstructive hypertrophic cardiomyopathy
Friday 3 September  
09.15 ESVC-O-9 Malcolm Reproducibility and repeatability of radiographic measurements of cardiac size in dogs
09.30 ESVC-O-11 Kuo An international survey of preferences for echocardiographic assessment of left atrial size in dogs: The BENEFIT Project
09.45 ESVC-O-12 Lekane Left Ventricular Eccentricity index for assessment of precapillary pulmonary hypertension in dogs
10.00 ESVC-O-13 Oliveira Continuous heart rate monitoring by Holter and validation of heart rate spot-checks to measure circadian variation in heart rate in dogs with atrial fibrillation
10.15 ESVC-O-14 Saponaro Holter characterization of ventricular and supraventricular arrhythmia in English bulldogs with presumed arrhythmogenic cardiomyopathy before specific antiarrhythmic therapy (94 cases)
11.20 ESVC-O-15 Ward Renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy
11.35 ESVC-O-16 Fidanzio Effect of the sampling time on urinary electrolytes following furosemide administration in dogs with myxomatous mitral valve disease
11.50 ESVC-O-17 Patata Echocardiographic variables predictive of clinical signs in dogs with pulmonary stenosis
12.05 ESVC-O-18 Nisini Bioelectrical Impedance Analysis in dogs with right congestive heart failure before and after treatment: a pilot study
12.20 ESVC-O-19 Reimann Platelet aggregation response to pimobendan in Cavalier King Charles Spaniels with myxomatous mitral valve disease
12.35 ESVC-O-20 Franchini The Longitudinal Outcome Of Canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: baseline treatment characteristics
ESCG – European Society of Comparative Gastroenterology
Friday 3 September  
14.25 ESCG-O-1 Bernard Comparative analysis of the distribution and severity of the lesions within the digestive tract in feline low-grade intestinal T-cell lymphoma or lymphoplasmacytic enteritis
14.40 ESCG-O-2 Da Riz Short-term survival and associated factors after surgical intestinal biopsies in cats with chronic enteropathy
14.55 ESCG-O-3 Wu Identification of bacteria in pancreas, liver, and bile of apparently healthy cats using next generation 16S rRNA sequencing and standard bacteriological culture
15.10 ESCG-O-4 Collier Investigating fecal microbial transplant in dogs with inflammatory bowel disease: a pilot study
15.25 ESCG-O-5 Toresson Clinical effects of fecal microbiota transplantation in dogs with chronic enteropathy
15.40 ESCG-O-6 Kuijlaars Faecal bile acid profiles in dogs with chronic enteropathies versus healthy controls
15.55 ESCG-O-7 Sung Fecal fatty acid, cholesterol, and bile acid concentrations in cats with chronic enteropathy
16.30 ESCG-O-8 Walker Metabolomic serum profiling in dogs with chronic enteropathy
16.45 ESCG-O-9 Csukovich Taking the next step: Modelling infectious diseases in canine intestinal organoids
17.00 ESCG-O-10 Thomson Retrospective analysis of the association between hepatic pathology and DGGR lipase in canines with histologically normal pancreas
17.15 ESCG-O-11 Méric Colorectal polypoid masses in dogs: multicentre retrospective study of 53 cases
17.30 ESCG-O-12 Dupont Suspected acute hemorrhagic diarrhea syndrome in out-patients: A preliminary study of disease severity, treatment, outcome and client satisfaction
17.45 ESCG-O-13 Tamura Low-dose oral cobalamin supplementation ameliorated in serum cobalamin concentrations in dogs with chronic enteropathy when compared with small cell gastrointestinal lymphoma
18.00 ESCG-O-14 Muradas Assessment of visceral pain in dogs with chronic enteropathy and its’ effect on behaviour and owner-observed quality of life
ESVNU – European Society of Veterinary Nephrology and Urology
Friday 3 September  
09.45 ESVNU-O-1 Kongtasai Urinary liver-type fatty acid-binding protein in cats with International Renal Interest Society (IRIS) stage 1 chronic kidney disease within a healthy elderly cohort
10.00 ESVNU-O-2 Tang Risk factors and implications associated with renal mineralisation in feline chronic kidney disease (CKD)
10.15 ESVNU-O-3 Lippi Erythrogram patterns in chronic kidney disease of dogs
11.20 ESVNU-O-4 Scarpa Evaluation of the clinical efficacy of benazepril in the treatment of renal proteinuria in dogs
11.35 ESVNU-O-5 Rimer Acute kidney injury in dogs: Etiology, clinical and clinicopathologic findings, prognostic markers, and outcome
11.50 ESVNU-O-6 Brans Effect of storage conditions and measurement device on serum Symmetric dimethylarginine in cats and dogs
12.05 ESVNU-O-7 Harrer Bacterial urinary tract infection and subclinical bacteriuria in dogs receiving chemotherapy: a prospective observational longitudinal clinical study
12.20 ESVNU-O-9 Duperrier-Simond Occurrence of cardio-vascular events in cats with acute urinary tract obstruction
ESVE – European Society of Veterinary Endocrinology
Saturday 4 September  
08.15 ESVE-O-1 Tardo Prospective evaluation of the prevalence of eunatraemic, eukalaemic hypoadrenocorticism in dogs with chronic gastrointestinal signs and risk of misdiagnosis in dogs with previous glucocorticoid administration
08.30 ESVE-O-2 Aguiar Development and characterisation of feline thyroid organoids as an in vitro model for feline hyperthyroidism research
08.45 ESVE-O-3 Scheemaeker Organoids of canine medullary thyroid carcinoma and feline thyroid adenomatous hyperplasia
09.00 ESVE-O-4 Bree Multicentre retrospective review of clinical features and short-term follow-up of 110 cases of canine primary hypoparathyroidism
09.15 ESVE-O-5 Corsini A prediction tool for diagnosis of canine hypothyroidism in clinical practice
09.30 ESVE-O-6 Carvalho Diagnosis of naturally-occuring hypercortisolism by primary care veterinarians: a western European survey
09.45 ESVE-O-7 Bunn Association of proteinuria with fasting hypertriglyceridaemia and hyperadrenocorticism in Australian Miniature Schnauzers
10.00 ESVE-O-8 Schofield Role of internal medicine specialists in disseminating the evolving evidence base on Cushing’s syndrome
10.15 ESVE-O-9 Da Riz Fibroblast Growth Factor-23 and phosphate metabolism in dogs with spontaneous hyperadrenocorticism (HAC)
11.05 ESVE-O-10 Golinelli Evaluation of clinical, ultrasonographic, and clinicopathological findings in dogs with pituitary-dependent hypercortisolism and poor trilostane response
11.20 ESVE-O-11 Rapastella Outcome in dogs with and without hyperadrenocorticism undergoing radiotherapy for pituitary macroadenomas
11.35 ESVE-O-12 Miceli Cabergoline treatment for feline hypersomatotropism
11.50 ESVE-O-13 Callegari Proteomic analysis in serum of cats with diabetes mellitus
12.05 ESVE-O-14 Nivy Effect of periodontal treatment on glycemic control in canine diabetic patients: a prospective, clinical study
12.20 ESVE-O-15 del Baldo The usefulness of different freestyle libre-derived metrics in assessing glycemic control in diabetic dogs
12.35 ESVE-O-16 Jaffey Effects of calcitriol on leukocyte cytokine production in dogs with diabetes mellitus
ESVONC – European Society of Veterinary Oncology
Saturday 4 September  
09.15 ESVONC-O-1 Troedson Change of feline injection site sarcoma incidence and localization within the last 30 years
09.30 ESVONC-O-2 Chalfon An update on environmental risk factors for the development of feline oral squamous cell carcinoma
09.45 ESVONC-O-3 Faroni Possible association between anesthesia and recurrence in dogs with medium/large B-cell lymphoma in complete remission after chemo – immunotherapy
10.00 ESVONC-O-4 Gedon BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: a retrospective study (2006-2019)
11.20 ESVONC-O-6 Mason Outcomes of Dogs with Anal Sac Gland Carcinoma Treated With Surgery and Adjunctive Radiotherapy in Ten 3.6Gy Fractions
11.35 ESVONC-O-7 Kritsotalaki Evaluation of outcome and toxicity in dogs undergoing “quad shot” radiation therapy for anal gland adenocarcinoma: a single center retrospective study of 17 cases
11.50 ESVONC-O-8 Lappalainen High–grade feline gastrointestinal lymphoma in 43 cases: one treatment does not fit them all
12.05 ESVONC-O-9 Marconato A phase 2, single-arm, open-label clinical trial on adjuvant active immunotherapy in dogs with appendicular osteosarcoma undergoing amputation and chemotherapy
12.20 ESVONC-O-10 Busser Impact of a 10% dose reduction and length of treatment delays in the management of chemotherapy-induced neutropenia in dogs: a single-centre experience
12.35 ESVONC-O-11 Chavalle Pharmacokinetic study of doxorubicin in cancer-bearing dogs: validation of a simple high-performance liquid chromatography (HPLC) method in 10 dogs